Clinical Trial of Continuous Infusion Verapamil, Bolus Vinblastine, and Continuous Infusion VP-16 in Drug-resistant Pediatric Tumors

摘要: Abstract We optimized the modulation of drug resistance by irreversible augmentation cytotoxicity coincubating vinblastine (VNB) with VP-16 and reversible increase in coincubation verapamil (VPL) VNB VP-16. VPL was administered as a loading dose (i.v.) (0.15 mg/kg) then constant infusion (0.005 over 6 days. 24 h after verapamil, 2 mg/m2 IVP followed 1 later 5-day simultaneous continuous (200 mg/m2/day) to seven pediatric patients (11 courses) refractory malignancies. The mean age at treatment 7.5 ± 5.3 years, prior anthracycline (303 210 mg/m2) range 0–606 mg/m2. Toxicity limited cardiac hematological. median nadir WBC 900 14.5 0.5 days platelet count 32,000 15.5 0.8 There were two episodes bacterial sepsis both which responded i.v. antibiotics. Five 11 courses resulted first-degree block one course second-degree block. At Hour 120 PR interval 0.18 0.01 versus 0.13 0 (P